Article
Pharmacology & Pharmacy
Xiaoyan Liu, Yitian Lang, Qingqing Chai, Yan Lin, Yahui Liao, Yizhun Zhu
Summary: Based on the IMvigor130 trial, adding atezolizumab to chemotherapy is effective in treating metastatic urothelial cancer. However, it is not a cost-saving option compared to chemotherapy in both American and Chinese settings.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Urology & Nephrology
Michiel S. van der Heijden, Yohann Loriot, Ignacio Duran, Alain Ravaud, Margitta Retz, Nicholas J. Vogelzang, Betty Nelson, Jingjing Wang, Xiaodong Shen, Thomas Powles
Summary: The study demonstrates the long-term durable remission effect of atezolizumab in patients with mUC after platinum-based chemotherapy, with fewer treatment-related adverse events and treatment discontinuation. This supports the use of atezolizumab in this patient population.
Article
Medicine, Research & Experimental
Shuxia Qin, Lidan Yi, Sini Li, Chongqing Tan, Xiaohui Zeng, Liting Wang, Ye Peng, Xiaomin Wan
Summary: The study evaluated the cost-effectiveness of atezolizumab plus platinum-based chemotherapy as first-line therapy for mUC from the US payer perspective. Results showed that atezolizumab group provided additional QALYs and had an incremental cost, with a high cost-effectiveness ratio compared to the placebo group. Subgroup analysis and sensitivity analyses were conducted to explore the model robustness and revealed the need for real-world data validation in extrapolations.
ADVANCES IN THERAPY
(2021)
Article
Oncology
Mark A. Socinski, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodriguez-Abreu, Denis Moro-Sibilot, Christian A. Thomas, Fabrice Barlesi, Gene Finley, Shengchun Kong, Anthony Lee, Shelley Coleman, Wei Zou, Mark McCleland, Geetha Shankar, Martin Reck
Summary: The final analysis of IMpower150 study showed a numerical OS improvement with ACP compared to BCP in metastatic nonsquamous NSCLC patients, while ABCP demonstrated continued OS improvement in all patients.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Toyohiro Yamada, Keita Nakane, Torai Enomoto, Masayuki Tomioka, Tomoki Taniguchi, Takashi Ishida, Kaori Ozawa, Kimiaki Takagi, Hiroki Ito, Shinichi Takeuchi, Makoto Kawase, Kota Kawase, Daiki Kato, Manabu Takai, Koji Iinuma, Shigeaki Yokoi, Masahiro Nakano, Takuya Koie
Summary: This study retrospectively evaluated the oncological outcomes of mUC patients who received pembrolizumab after platinum-based chemotherapy. Patients in the treatment group had better overall survival and progression-free survival.
Article
Oncology
Xiaoling Shang, Jianxiang Shi, Xiaohui Wang, Chenglong Zhao, Haining Yu, Haiyong Wang
Summary: A nomogram model based on clinical variables was established to predict the survival in NSCLC patients receiving second-line atezolizumab. Patients were divided into high- and low-risk groups, with high-risk patients showing worse overall survival in both training and test cohorts. All patients benefited from atezolizumab compared with docetaxel.
Article
Oncology
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paolo Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Giuseppe Curigliano, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia
Summary: The ANASTASE study retrospectively analyzed data from PD-L1-positive mTNBC patients treated with atezolizumab plus nab-paclitaxel and found similar results in terms of PFS and ORR as reported in the IMpassion130 study, with no unexpected adverse events.
Article
Oncology
L. A. Emens, S. Adams, C. H. Barrios, V Dieras, H. Iwata, S. Loi, H. S. Rugo, A. Schneeweiss, E. P. Winer, S. Patel, V Henschel, A. Swat, M. Kaul, L. Molinero, S. Patel, S. Y. Chui, P. Schmid
Summary: The study showed that although A + nP for first-line treatment of triple-negative breast cancer did not significantly improve overall survival in the overall population, clinically meaningful benefits were observed in patients with PD-L1 expression on tumor infiltrating immune cells. The combination therapy remained safe and tolerable with longer follow-up.
ANNALS OF ONCOLOGY
(2021)
Article
Urology & Nephrology
Deniz Tural, Omer Fatih Olmez, Ahmet Taner Sumbul, Mehmet Artac, Nail Ozhan, Emre Akar, Burcu Cakar, Osman Kostek, Meltem Ekenel, Mustafa Erman, Hasan Senol Coskun, Fatih Selcukbiricik, Ozge Keskin, Fatma Paksoy Turkoz, Kerem Oruc, Selami Bayram, Ugur Yglmaz, Irem Bilgetekin, Birol Ygldgz, Mehmet Ali Nahit Sendur, Nail Paksoy, Ahmet Dirican, Dilek Erdem, Meltem Selam, Ozgur Tanrgverdi, Semra Paydas, Zuhat Urakcg, Elif Atag, Sabri Guncan, Yuksel Urun, Ali Alkan, Ali Osman Kaya, Deniz Tataroglu Ozyukseler, Halil Taskaynatan, Mustafa Ygldgrgm, Muge Sonmez, Tugba Basoglu, Seyda Gunduz, Saadettin Kglgckap
Summary: This study analyzed data from 115 patients with metastatic bladder cancer treated with atezolizumab, finding it to be effective and well tolerated in patients who had progressed with previous treatment. Despite some limitations, the results are consistent with previous clinical trial outcomes.
EUROPEAN UROLOGY FOCUS
(2021)
Article
Oncology
Min Jin Ha, Akshara Singareeka Raghavendra, Nicole M. Kettner, Wei Qiao, Senthil Damodaran, Rachel M. Layman, Kelly K. Hunt, Yu Shen, Debu Tripathy, Khandan Keyomarsi
Summary: This study analyzed the Breast Medical Oncology database at MD Anderson Cancer Center to assess the effectiveness of the CDK4/6 inhibitor palbociclib plus endocrine therapy compared to endocrine therapy alone in patients with advanced hormone receptor-positive, HER2-negative breast cancer. The results showed that palbociclib in combination with endocrine therapy was associated with improved progression-free survival in both first-line and second-line settings, as well as improved overall survival in the second-line setting.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Hubert Kamecki, Malgorzata Debowska, Jan Poleszczuk, Tomasz Demkow, Artur Przewor, Lukasz Nyk, Roman Sosnowski
Summary: Bladder cancer patients diagnosed incidentally tend to have improved survival, especially if the bladder lesion was first visualized with an ultrasound. However, the improved survival might be caused by overdiagnosis of low-grade cancer. This study provides important evidence for the discussion on the role of screening for bladder cancer.
Article
Medicine, General & Internal
Jessica C. Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, Jean-Francois Baurain, Max Schlaak, Marcus O. Butler, Ryan J. Sullivan, Reinhard Dummer, John M. Kirkwood, Marlana Orloff, Joseph J. Sacco, Sebastian Ochsenreither, Anthony M. Joshua, Lauris Gastaud, Brendan Curti, Josep M. Piulats, April K. S. Salama, Alexander N. Shoushtari, Lev Demidov, Mohammed Milhem, Bartosz Chmielowski, Kevin B. Kim, Richard D. Carvajal, Omid Hamid, Laura Collins, Koustubh Ranade, Chris Holland, Constance Pfeiffer, Paul Nathan
Summary: This study reported the 3-year efficacy and safety results of tebentafusp, showing a continued long-term survival benefit for adult patients with previously untreated metastatic uveal melanoma who are positive for HLA-A*02:01.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Urology & Nephrology
Bernadett Szabados, Mark Kockx, Zoe June Assaf, Pieter-Jan van Dam, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, Michiel S. Van Der Heijden, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Diana Stanoeva, Sofie Daelemans, Miche Rombouts, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Shruti Sharma, Alexey Aleshin, Romain Banchereau, Daniel Castellano, Thomas Powles
Summary: The results of the ABACUS trial showed that neoadjuvant atezolizumab in MIBC is associated with significant clinical responses and high DFS. CD8+ expression and serial ctDNA levels are correlated with outcomes and may contribute to personalized therapy in the future.
Article
Medicine, General & Internal
Dan Su, Bin Wu, Lizheng Shi
Summary: Cost-effectiveness evaluation of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma from the US payer perspective showed that the treatment is unlikely to be cost-effective compared with sorafenib. Lowering the prices of atezolizumab and bevacizumab may enhance cost-effectiveness, and tailoring treatments based on individual patient factors could also improve economic outcomes.
Article
Oncology
Kristen D. Whitaker, Xiaoliang Wang, Mustafa Ascha, Timothy N. Showalter, Heather G. Lewin, Gregory S. Calip, Lori J. Goldstein
Summary: Black women in the USA have higher incidence and mortality of metastatic breast cancer, while Hispanic women have lower rates. This study found racial differences in treatment and survival among patients with HR+HER2- mBC, with Black women experiencing worse survival, especially among those who did not receive first-line treatment. However, there was no significant impact of racial differences on survival among patients who received first-line treatment.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
